Christian Angermayer
Showing 1–3 of 3 transcripts.
- Milken Institute49 min
Can Psychedelics Improve Mental Health? With C. Angermayer & Uma Thurman | Global Conference 2021
C. Angermayer, Uma Thurman, Christian Angermayer, Robert Mancini
German biotech investor Christian Angermeyer founded Atai Life Sciences to develop psychedelic therapeutics capable of treating over one billion people suffering from mental health conditions that current standard medications often fail to address. By targeting the brain's Default Mode Network to induce neuroplasticity, Angermeyer's pipeline includes non-addictive compounds like psilocybin and MDMA intended to be administered under strict medical supervision rather than for recreational use. The strategic goal is to reclassify these substances through rigorous FDA protocols to resolve widespread anxiety, addiction, and trauma while eventually fostering broader societal reconciliation as medical efficacy becomes undeniable.
- The Diary Of A CEO1h 48m
A Billionaire’s Guide To Healing Your Mind And Extending Your Life: Christian Angermayer | E72
Christian Angermeyer, a prominent European investor who co-founded Compass Pathways and Atai Life Sciences, is driving a global revolution in the psychedelics industry through his early adoption of the compounds and his conviction that they are essential for treating addiction and mental health. His philosophy extends beyond finance to a radical vision of human longevity, where he predicts death will become a chosen event as biotechnology reverses aging, while he advocates for psychedelics to help society adapt to the psychological upheaval caused by rapid technological acceleration. Angermeyer combines this foresight with a rigorous personal regimen of discipline, intermittent fasting, and Bitcoin investment, aiming to integrate work and passion to live a purposeful, self-actualized life free from traditional societal constraints.
- Milken Institute59 min
Psychedelics: Mind-Enhancing Methods to Well-Being
Tim Ferriss, Christian Angermayer, Robin Carhart-Harris, Matthew Johnson, Ayelet Waldman
In 1957, Katherine McCormick's pivotal funding enabled Gregory Pincus to develop the oral contraceptive, establishing a historical precedent for high-conviction scientific bets that now mirrors the current push to reclassify psychedelics like psilocybin and MDMA from Schedule I to Schedule IV. Recent clinical trials demonstrate these substances' efficacy in treating treatment-resistant depression, anxiety in cancer patients, and addiction, with effects often lasting months after a single session compared to the temporary relief provided by conventional SSRIs. Supported by major funding from investors like Christian Angermeyer and research from institutions such as Johns Hopkins and Imperial College London, the movement aims to integrate these therapies into a regulated medical model to address the growing global mental health crisis.